blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3701950

EP3701950 - METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL PL3K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.07.2023
Database last updated on 13.09.2024
FormerRequest for examination was made
Status updated on  05.03.2021
FormerThe application has been published
Status updated on  31.07.2020
Most recent event   Tooltip28.07.2023Application deemed to be withdrawnpublished on 30.08.2023  [2023/35]
Applicant(s)For all designated states
Rhizen Pharmaceuticals S.A.
Fritz Courvoisier 40
2300 La Chaux de Fonds / CH
[2020/36]
Inventor(s)01 / Kumar Venkata Satya Vakkalanka, Swaroop
Fritz Courvoisier 40
2300 La Chaux de Fonds / CH
02 / Viswanadha, Srikant
c/o Incozen Therapeutics Pvt. Ltd. 450-Alexandria
Knowledge Park, Shameerpet
500078 Hyderabad / IN
 [2020/36]
Representative(s)Haseltine Lake Kempner LLP
Bürkleinstrasse 10
80538 München / DE
[2020/36]
Application number, filing date20166664.103.09.2015
[2020/36]
Priority number, dateIN2014CHE428703.09.2014         Original published format: IN 4287CH2014
[2020/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3701950
Date:02.09.2020
Language:EN
[2020/36]
Search report(s)(Supplementary) European search report - dispatched on:EP07.07.2020
ClassificationIPC:A61K31/519, A61K31/56, A61K31/573, A61K45/06, A61P37/00, A61P11/06, A61P11/00
[2020/36]
CPC:
A61K31/519 (EP,AU,EA,IL,KR,US); A61K45/06 (EP,EA,IL,KR,US); A61K31/56 (EP,AU,EA,IL,KR,US);
A61K31/573 (EP,AU,EA,IL,KR,US); A61P1/04 (EP,IL); A61P1/16 (EP,IL);
A61P11/00 (EP,AU,EA,IL); A61P11/02 (EP,IL); A61P11/06 (EP,AU,EA,IL);
A61P11/16 (EP,IL); A61P13/10 (EP,IL); A61P13/12 (EP,IL);
A61P15/02 (EP,IL); A61P17/00 (EP,IL); A61P17/02 (EP,IL);
A61P17/04 (EP,IL); A61P17/06 (EP,IL); A61P17/10 (EP,IL);
A61P19/02 (EP,IL); A61P19/04 (EP,IL); A61P19/10 (EP,IL);
A61P21/00 (EP,IL); A61P21/04 (EP,IL); A61P25/00 (EP,IL);
A61P27/14 (EP,IL); A61P29/00 (EP,IL); A61P3/10 (EP,IL);
A61P37/00 (EP,EA,IL); A61P37/02 (EP,IL); A61P37/06 (EP,AU,IL);
A61P37/08 (EP,IL); A61P43/00 (EP,IL); A61P5/14 (EP,IL);
A61P7/06 (EP,IL); A61P9/14 (EP,IL); A61K2300/00 (AU,IL,KR) (-)
C-Set:
A61K31/519, A61K2300/00 (AU,EP,US);
A61K31/56, A61K2300/00 (US,AU,EP);
A61K31/573, A61K2300/00 (US,AU,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/14]
Former [2020/36]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR BEHANDLUNG UND ZUSAMMENSETZUNGEN MIT DUAL-PL3K-DELTA-GAMMA-KINASE-INHIBITOR UND EINEM KORTIKOSTEROID[2020/36]
English:METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL PL3K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID[2020/36]
French:PROCÉDÉ DE TRAITEMENT ET COMPOSITIONS COMPRENANT UN INHIBITEUR DOUBLE DE LA KINASE PL3K DELTA-GAMMA ET UN CORTICOSTÉROÏDE[2020/36]
Examination procedure01.03.2021Amendment by applicant (claims and/or description)
01.03.2021Examination requested  [2021/14]
01.03.2021Date on which the examining division has become responsible
01.04.2023Application deemed to be withdrawn, date of legal effect  [2023/35]
21.04.2023Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2023/35]
Parent application(s)   TooltipEP15774713.0  / EP3188759
Fees paidRenewal fee
29.07.2020Renewal fee patent year 03
29.07.2020Renewal fee patent year 04
29.07.2020Renewal fee patent year 05
29.09.2020Renewal fee patent year 06
27.09.2021Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.09.202208   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2012151525  (RHIZEN PHARMACEUTICALS SA [CH], et al) [X] 1-15 * table 1; compounds 6,6a,6b * * paragraphs [0089] , [0093] , [0182] , [0185] , [0226] , [0562] * * table 2 * * page 217, lines 1-6,24,31,34 *;
 [X]WO2014072937  (RHIZEN PHARMACEUTICALS SA [CH]) [X] 1-15 * paragraphs [0002] , [0024] , [0033] , [0036] , [0075] , [0090] ** compound Compound A1 *
by applicantGB1578446
 WO2006005611
 WO2009088986
 WO2009088990
 WO2010002804
 WO2011008302
 WO2011029547
 WO2012097000
 WO2012123482
    - HIRSCH et al., Pharmacol. Ther., (20080000), vol. 118, pages 192 - 205
    - MARONE et al., Biochim. Biophys. Acta, (20080000), vol. 1784, pages 159 - 185
    - ROMMEL et al., Nat. Rev. Immunol., (20070000), vol. 7, pages 191 - 201
    - RUCKLE et al., Nat. Rev. Drug Discov., (20060000), vol. 5, pages 903 - 918
    - KONRAD et al., J. Biol. Chem., (20080000), vol. 283, pages 33296 - 33303
    - LAFFARGUE et al., Immunity, (20020000), vol. 16, pages 441 - 451
    - ALI et al., J. Immunol., (20080000), vol. 180, pages 2538 - 2544
    - JOU et al., Mol. Cell. Biol., (20020000), vol. 22, pages 8580 - 8591
    - CLAYTON et al., J. Exp. Med., (20020000), vol. 196, pages 753 - 763
    - THOMPSON et al., Chemistry & Biology, (20100000), vol. 17, pages 101 - 102
    - PIXU LIU, Nature Reviews Drug Discovery, (20090000), vol. 8, pages 627 - 644
    - NATHAN T., Mol Cancer Ther., (20090100), vol. 8, no. 1
    - ROMINA MARONE et al., Biochimica et Biophysica Acta, (20080000), vol. 1784, pages 159 - 185
    - M.J. GREEN et al., J. Med. Chem., (19820000), vol. 25, pages 1492 - 1495
 US20100938609
 WO2012US36594
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.